FDA to discuss fluoroquinolones, drug compounding

FDA said it will hold two upcoming advisory committee meetings.

The agency's Antimicrobial Drug Advisory and Drug Safety and Risk Management advisory committees will meet Nov. 5 to discuss risks and benefits of fluoroquinolone antibacterial drugs to treat acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis in patients with chronic obstructive pulmonary disease (COPD) and uncomplicated urinary tract infections. ...